Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly

BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To eval...

Full description

Saved in:
Bibliographic Details
Main Authors: Jerson Laks, Eliasz Engelhardt, Valeska Marinho, Marcia Rozenthal, Fernando de Castro e Souza, Josué Bacaltchuk, Alberto Stoppe Jr., R.C.R. Ferreira, Cassio Bottino, Mônica Scalco
Format: Article
Language:English
Published: Thieme Revinter Publicações 2001-12-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2001000600005&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850248444216606720
author Jerson Laks
Eliasz Engelhardt
Valeska Marinho
Marcia Rozenthal
Fernando de Castro e Souza
Josué Bacaltchuk
Alberto Stoppe Jr.
R.C.R. Ferreira
Cassio Bottino
Mônica Scalco
author_facet Jerson Laks
Eliasz Engelhardt
Valeska Marinho
Marcia Rozenthal
Fernando de Castro e Souza
Josué Bacaltchuk
Alberto Stoppe Jr.
R.C.R. Ferreira
Cassio Bottino
Mônica Scalco
author_sort Jerson Laks
collection DOAJ
description BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.
format Article
id doaj-art-188a039a7d324b3e8a3d25d62faa7a8f
institution OA Journals
issn 1678-4227
language English
publishDate 2001-12-01
publisher Thieme Revinter Publicações
record_format Article
series Arquivos de Neuro-Psiquiatria
spelling doaj-art-188a039a7d324b3e8a3d25d62faa7a8f2025-08-20T01:58:42ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria1678-42272001-12-0159485986410.1590/S0004-282X2001000600005Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderlyJerson Laks0Eliasz Engelhardt1Valeska Marinho2Marcia Rozenthal3Fernando de Castro e Souza4Josué Bacaltchuk5Alberto Stoppe Jr.6R.C.R. Ferreira7Cassio Bottino8Mônica Scalco9Universidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloBACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2001000600005&tlng=enrisperidonedementiaBPSDelderly
spellingShingle Jerson Laks
Eliasz Engelhardt
Valeska Marinho
Marcia Rozenthal
Fernando de Castro e Souza
Josué Bacaltchuk
Alberto Stoppe Jr.
R.C.R. Ferreira
Cassio Bottino
Mônica Scalco
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
Arquivos de Neuro-Psiquiatria
risperidone
dementia
BPSD
elderly
title Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_full Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_fullStr Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_full_unstemmed Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_short Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_sort efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
topic risperidone
dementia
BPSD
elderly
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2001000600005&tlng=en
work_keys_str_mv AT jersonlaks efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT eliaszengelhardt efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT valeskamarinho efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT marciarozenthal efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT fernandodecastroesouza efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT josuebacaltchuk efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT albertostoppejr efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT rcrferreira efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT cassiobottino efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly
AT monicascalco efficacyandsafetyofrisperidoneoralsolutioninagitationassociatedwithdementiaintheelderly